Work

An immunological mechanism of resistance to CDK4/6 inhibitors in HR + breast cancer

Year: 2025

Type: editorial

Abstract: CDK4/6 inhibitors are central to the clinical management of HR+HER2− breast cancer. We have recently demonstrated that immunosuppressive, IL17-secreting γδ T cells recruited to the tumor microenvironment by a CCL2-dependent mechanism upon CDK4/6 inhibition can repolarize tumor-associated macrophages toward a CX3CR1+ phenotype associated with resistance to therapy.

Source: OncoImmunology

DOI: 10.1080/2162402x.2025.2520269

Authors: Claudia Galassi, Giulia Petroni, Simon R.V. Knott, Lorenzo Galluzzi

Institutions: Weill Cornell Medicine, University of Florence, Cedars-Sinai Medical Center, Fox Chase Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913